Prime Medicine, Inc. (NASDAQ: PRME) is a Healthcare company (Biotechnology) with a market capitalization of $699M. The Maz Rating grades it against the other companies in its sector.
Prime Medicine, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.84, Prime Medicine, Inc. trades at 99.2x sales and 81.2x book value. Over the last twelve months it generated about $7M of revenue and a net loss of $181M. It runs a gross margin of 48.8%, an operating margin of -2584.2% and a net margin of -2497.6%. It shows return on equity of -287.0%, return on invested capital of -97.2% and a free cash flow yield of -22.7%. On the balance sheet: a debt-to-equity ratio of 13.09 and a current ratio of 1.79. Over the past 52 weeks the share price ranged from $2.67 to $5.91, with a beta of 2.15.
Prime Medicine, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 7 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Prime Medicine, Inc. (PRME) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 9.42% / 30% · Interest income / Revenue 13.2% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 9.42% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 13.2% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 9.42% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 13.2% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 19.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 42.7% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 13.2% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 28.6% / 33.33% · (Cash+Recv) / Total Assets 28.6% / 33.33% · Interest income / Revenue 13.2% / 5% | Fail |
No. As of September 2026, Prime Medicine, Inc. (PRME) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Prime Medicine, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 13.2% of each dividend: Prime Medicine, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.